Amzak Capital Management

Sound Blade Medical is an early-stage medical device company that specializes in developing innovative, non-invasive therapies using endoscopic histotripsy. This technology employs focused ultrasound, guided by real-time imaging, to precisely destroy targeted tissue without heat, ionizing radiation, or surgical invasion. The company aims to revolutionize healthcare by enhancing endoscopic procedures, offering a more precise and safer alternative to traditional treatments.

ShiraTronics, Inc. is a company that specializes in developing and commercializing neuromodulation therapies aimed at treating chronic migraines, a condition that significantly impacts the lives of millions worldwide. Founded in 2018 and headquartered in Ireland, with an additional location in Minneapolis, Minnesota, ShiraTronics is focused on addressing unmet clinical needs in neurology. The company's innovative technologies offer new approaches to effectively alleviate the debilitating effects of migraine headaches, thereby striving to improve the quality of life for those affected by this disabling disorder.

HistoSonics, Inc. is a medical technology company based in Plymouth, Minnesota, specializing in non-invasive tumor ablation systems. The company has developed the Edison Platform, which employs advanced imaging and proprietary sensing technology to deliver precise sonic beam therapy. This innovative platform utilizes histotripsy and focused sound energy to liquefy and destroy targeted tissues at the sub-cellular level, enabling personalized treatments. HistoSonics' technology allows physicians to monitor the treatment in real time, offering a safe alternative to traditional interventional and surgical methods, minimizing undesirable side effects often associated with these approaches. Incorporated in 2009, HistoSonics aims to enhance treatment outcomes through its pioneering non-invasive solutions.

Synergy Disc Replacement Inc(SDRI) produces Cervical disc implant to restore patient's balance, range of motion and alignment.

Gynesonics, Inc. is a medical device company that focuses on designing and developing minimally invasive solutions for symptomatic uterine fibroids in women. Established in 2005 and headquartered in Redwood City, California, with an additional location in Beuningen, the Netherlands, the company offers the Sonata System, which utilizes sonography-guided transcervical fibroid ablation for the treatment of fibroids under intrauterine sonography guidance. Gynesonics aims to provide a safe and effective incisionless alternative to traditional surgical techniques such as hysterectomy and myomectomy, thereby enabling women to receive painless treatments for severe menstrual symptoms associated with fibroids.

Miach Orthopaedics is a medical device company based in Westborough, Massachusetts, founded in 2016. The company specializes in developing bio-engineered surgical implants aimed at facilitating new tissue growth and aiding in connective tissue repair. Its primary product, the Bridge-Enhanced ACL Repair technology, offers a viable alternative to traditional anterior cruciate ligament (ACL) reconstruction for patients who have suffered ACL injuries. This innovative approach enables surgeons to restore the normal anatomy and function of the knee, enhancing recovery outcomes for patients.

Thryv Therapeutics is a precision medicine company focused on developing innovative therapies for Long QT Syndrome and various arrhythmias. The company employs a precision medicine approach to address both genetic and drug-induced long QT syndrome, atrial fibrillation, and treatment-resistant cancers. Thryv Therapeutics is dedicated to creating potent and selective inhibitors of Serum Glucocorticoid Inducible Kinase, aiming to reduce the risk of sudden cardiac death and enhance the quality of life for affected patients. Through its targeted therapeutic development, the company seeks to provide effective solutions for serious cardiovascular and oncological conditions.

Neuros Medical, Inc. is a neuromodulation company based in Willoughby Hills, Ohio, that specializes in developing proprietary neurostimulation therapies aimed at addressing unmet medical needs for patients globally. The company's flagship technology, known as Electrical Nerve Block, targets chronic pain conditions, including neuroma and residual limb pain, chronic post-surgical pain, and chronic migraine. Neuros Medical also offers the Neuros Altius System, which features an implantable generator with an integrated rechargeable battery, a cuff electrode, and associated external devices. Established in 2008, the company is dedicated to advancing innovative solutions for pain management.

Reneo Pharmaceuticals is a clinical-stage pharmaceutical company based in San Diego, California, that focuses on developing therapies for patients with rare genetic mitochondrial diseases. These conditions are linked to defects in energy metabolism, leading to issues such as muscle weakness and wasting. The company is developing REN001, an oral drug designed to modulate genes involved in mitochondrial function, aiming to enhance adenosine triphosphate (ATP) production, which is essential for cellular energy. By improving mitochondrial activity, Reneo seeks to enhance the daily functioning and quality of life for patients suffering from these disorders. Founded in 2014, Reneo Pharmaceuticals is committed to addressing the needs of individuals with orphan metabolic diseases.

Monte Rosa Therapeutics is a biotechnology company focused on developing innovative cancer therapeutics that utilize molecular glue degraders (MGDs) to modulate protein degradation pathways. By leveraging the body's natural mechanisms for protein destruction, these small molecule drugs selectively target and degrade disease-causing proteins. The company employs its QuEEN platform, which combines artificial intelligence and proprietary experimental tools, to identify relevant proteins for degradation. With a diverse library of over 50,000 MGD molecules, Monte Rosa's lead candidate, MRT-2359, specifically targets the translation termination factor protein GSPT1, showing promise for treating MYC-driven tumors. The company aims to advance its pipeline of pioneering therapies for cancer and other diseases.

Impulse Dynamics N.V. is a medical device company focused on developing electrical therapies for chronic heart failure, operating primarily in the United States and Europe. The company's key innovation is its cardiac contractility modulation (CCM) therapy, which utilizes non-excitatory electrical impulses delivered to the heart muscles. This therapy aims to enhance cardiac strength and improve blood flow, offering a minimally invasive treatment option for patients with limited alternatives. Impulse Dynamics conducts clinical trials to assess the safety and efficacy of its therapies and collaborates with universities and hospitals for research initiatives. Founded in 1996 and headquartered in Willemstad, Curacao, the company also maintains offices in New York and Hong Kong, alongside product development centers in New Jersey and Israel.

ShiraTronics, Inc. is a company that specializes in developing and commercializing neuromodulation therapies aimed at treating chronic migraines, a condition that significantly impacts the lives of millions worldwide. Founded in 2018 and headquartered in Ireland, with an additional location in Minneapolis, Minnesota, ShiraTronics is focused on addressing unmet clinical needs in neurology. The company's innovative technologies offer new approaches to effectively alleviate the debilitating effects of migraine headaches, thereby striving to improve the quality of life for those affected by this disabling disorder.

Bellus Health is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for rare diseases, with a particular focus on conditions affecting the kidneys. Its lead drug candidate, KIACTA™, is designed for the treatment of AA amyloidosis, a rare condition that can result in severe renal dysfunction. Following the successful completion of a Phase 3 study, the company is collaborating with Auven Therapeutics to advance KIACTA™, which is also being explored for treating sarcoidosis, an inflammatory disease affecting the lungs. Additionally, Bellus Health is developing Shigamab™, an antibody treatment for Hemolytic Uremic Syndrome, a serious condition linked to Shiga toxin-producing E. coli, which poses significant health risks, especially for children. The company's research pipeline also includes efforts to address AL amyloidosis, another rare disease characterized by the accumulation of amyloid proteins in the body. Bellus Health aims to meet the high unmet medical needs of patients suffering from these conditions through its focused therapeutic developments.

Miach Orthopaedics is a medical device company based in Westborough, Massachusetts, founded in 2016. The company specializes in developing bio-engineered surgical implants aimed at facilitating new tissue growth and aiding in connective tissue repair. Its primary product, the Bridge-Enhanced ACL Repair technology, offers a viable alternative to traditional anterior cruciate ligament (ACL) reconstruction for patients who have suffered ACL injuries. This innovative approach enables surgeons to restore the normal anatomy and function of the knee, enhancing recovery outcomes for patients.

MEI Pharma, Inc. is a late-stage pharmaceutical company based in San Diego, California, dedicated to developing innovative therapies for cancer treatment. The company's clinical pipeline includes several key drug candidates such as Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor currently in Phase II trials for relapsed follicular lymphoma, and Voruciclib, an oral cyclin-dependent kinase inhibitor under investigation for acute myeloid leukemia and B-cell malignancies in Phase Ib trials. Additionally, MEI Pharma is developing ME-344, a mitochondrial inhibitor targeting HER2-negative breast cancer, and Pracinostat, an oral histone deacetylase inhibitor being tested for myelodysplastic syndrome. The company has established various collaborations and agreements with notable partners, including Kyowa Kirin Company and BeiGene, to support its clinical development efforts. Founded in 2000, MEI Pharma has evolved significantly since its inception and continues to focus on advancing its promising oncology therapies.

Eidos Therapeutics, Inc. is a clinical stage biopharmaceutical company based in San Francisco, California, that specializes in developing treatments for diseases related to transthyretin (TTR) amyloidosis. The company is advancing AG10, an orally administered small molecule currently in phase 3 clinical trials, which aims to stabilize tetrameric TTR and interrupt the molecular processes leading to amyloidosis. Founded in 2013, Eidos Therapeutics operates as a subsidiary of BridgeBio Pharma, which focuses on creating genetically targeted therapies designed to address the underlying causes of various diseases. Through its innovative approach, Eidos Therapeutics seeks to provide potentially disease-modifying therapies to meet the significant medical needs associated with TTR-related conditions.

GTx, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative treatments for stress urinary incontinence and prostate cancer. The company specializes in selective androgen receptor modulators (SARMs) and selective androgen receptor degraders, targeting conditions such as breast cancer and Duchenne muscular dystrophy. One of its notable product candidates is enobosarm GTx-024, which is undergoing Phase II clinical trials for patients with specific types of breast cancer and postmenopausal women suffering from stress urinary incontinence. Founded in 1997 and based in Memphis, Tennessee, GTx aims to advance medical solutions by leveraging new scientific approaches. In 2019, GTx was acquired by Oncternal Therapeutics in a reverse merger.

Inspire Medical Systems, Inc. is a medical technology company dedicated to developing and commercializing minimally invasive solutions for patients suffering from obstructive sleep apnea (OSA). Founded in 2007 and headquartered in Golden Valley, Minnesota, the company specializes in innovative implantable neurostimulation technologies. Its primary product, the Inspire system, utilizes a proprietary Upper Airway Stimulation (UAS) therapy that provides a safe and effective treatment for moderate to severe OSA. This technology leverages established principles from cardiac pacing and neurostimulation to deliver mild hypoglossal nerve stimulation, which helps maintain an open airway by continuously monitoring the patient's breathing. Inspire Medical Systems operates primarily in the United States and Europe, generating most of its revenue from the U.S. market.

Essential Medical, Inc. is a medical device company based in Malvern, Pennsylvania, that specializes in developing femoral artery vascular closure devices. Founded in 2010, the company focuses on sealing femoral punctures that occur after diagnostic and interventional cardiac catheterization procedures. Essential Medical has created two primary closure devices, including MANTA, which is specifically designed to address large bore punctures ranging from 10 to 24 French. These devices are particularly relevant for procedures such as transcatheter aortic valve replacement (TAVR), abdominal aortic aneurysm repair (AAA/PVAR), and balloon aortic valvuloplasty (BAV). The innovations from Essential Medical aim to fulfill a significant need in interventional cardiology by providing efficient closure solutions that minimize complications for patients. Since October 2018, the company operates as a subsidiary of Teleflex Incorporated.

Assurance Operations Corp. is a comprehensive engineering and manufacturing firm that focuses on custom metal fabrication and stamping. The company excels in designing, developing, testing, and managing programs for custom industrial packaging and material handling solutions. Assurance Operations Corp. produces a wide range of parts, including both light and heavy components made from aluminum, stainless steel, and steel, catering to various industrial needs.

KEW, Inc., established in 2009 and headquartered in Cambridge, Massachusetts, specializes in genomic testing services for cancer patients. The company's core offering, CANCERPLEX, is a precision medicine service that analyzes a patient's genetic drivers to help oncologists select personalized, targeted therapies. KEW's suite of products includes CANCERPLEX FP, a full panel test with immunotherapy options, CANCERPLEX TS for common tumor sites, and CANCERPLEX TX for FDA-approved targeted therapies. The company delivers these solutions through strategic partnerships and distributors, enabling evidence-driven treatment decisions in cancer care.

Marbles: The Brain Store is a specialty retailer focused on providing a diverse range of brain-building products, including games, puzzles, books, and educational toys. The store is designed to offer a hands-on shopping experience for families, allowing customers to explore and try unique items that promote cognitive development. Through interactive in-store experiences and online product demonstrations, Marbles helps individuals of all ages enhance critical thinking, memory, coordination, visual perception, and word skills. The emphasis on high-quality and engaging products positions Marbles as a destination for those seeking to nurture their mental acuity in an enjoyable manner.